



Essilor Stellest™ lens:
New spectacle lenses for myopia control and two-year clinical trial results.

JOIN OUR ESSILOR SPONSORED SATELLITE SESSION ON MYOPIA

25TH SEPT **5:30^{CEST} pm**




WSPOS Connect 2 the World
25th-26th September 2021

Two-year results of Essilor's Stellest™ lens, its breakthrough innovation to fight myopia progression in children, to be presented at WSPOS congress 2021

- Compelling two-year clinical trial results demonstrate that Essilor Stellest™ lens slows down myopia progression by 67%¹

(Charenton-le-Pont, 21 September, 2021) – Essilor will present the two-year clinical trial results of its breakthrough Stellest™ lens at the 'World Society of Paediatric Ophthalmology and Strabismus (WSPOS) Connect 2 the World' virtual congress 2021 on 25 September. The session will provide an international platform to interact with leading paediatric ophthalmologists, researchers, eye care practitioners and myopia experts on myopia management.

For the second year in a row, Essilor will participate at the conference, as part of its mission to engage, share insights and provide innovative solutions to address the growing problem of myopia together. To join Essilor's satellite session on 25 September at 17.30–18.30 CEST (11.30–12.30 EST), participants can click [here](#) to register for the conference.

The randomized three-year clinical trial started in July 2018 in the WEIRC (Wenzhou Medical University – Essilor International Research Center) in China on 167 myopic schoolchildren aged 8–13 years, who received three types of spectacle lenses - lenses with highly aspherical lenslets (HAL), lenses with slightly aspherical lenslets (SAL), and single-vision lenses. The clinical trial showed that higher lenslet asphericity led to higher myopia control efficacy, so HAL lenses were more effective at slowing down myopia progression than SAL lenses, when compared to single-vision lenses. Essilor Stellest™ lenses have the same optical design as the HAL lenses.

The study also demonstrated that the wearing time significantly influenced the treatment outcome. After two years, children wearing Essilor Stellest™ lenses saved 0.99 diopters of myopia

degree on average (67% slow-down in myopia progression on average), compared to single vision lenses, when worn 12 hours or more per day, every day¹.

During the satellite session, a review of the different generations of myopia control spectacle lenses, the design of the Essilor Stellest™ lens and the two-year clinical trial results will be presented by Dr. Damien Paillé, Dr. Guillaume Giraudet and Dr. Björn Drobe respectively, from Essilor International's research and development team. The session will be introduced by Dr. Ken Nischal, WSPOS Co-founder, and Olga Prenat, Vice President, Global Education and Professional Relations, Essilor International.

Norbert Gorny, Co-Chief Operating Officer, Essilor International, commented on the results, *"It has been well-established that early intervention is critical to preventing high myopia from developing. Given the increased risk of high myopia with myopia onset at a younger age, the Essilor Stellest™ lens can help in effectively slowing down myopia progression even during early childhood, reducing myopia-related risks later in life. So we truly hope that it is the catalyst for increased myopia management in practices globally. With this lens, we continue to lead the way in developing a safe, convenient and effective way to manage the increasing myopia problem."*

Grita Loeb sack, Group Chief Marketing Officer, Essilor International said, *"We are proud to collaborate with WSPOS for the second time and share our expertise and innovations with eye care practitioners at this important forum. This is part of our ongoing efforts to build partnerships to educate and equip eye care professionals on myopia globally. After its successful release in China, Russia, and Singapore in 2020, we have launched the Essilor Stellest™ lens in France and Italy this year. We will continue to expand our myopia footprint to protect our children's vision for the future."*

Dr. Ken Nischal, WSPOS Co-founder and Division Chief, Pediatric Ophthalmology, Strabismus, and Adult Motility Professor of Ophthalmology at the University of Pittsburgh, School of Medicine, said, *"Myopia management strategies are extremely important to embrace so that we can reduce the burden of related vision-threatening complications that may become apparent at the end of the second decade of life onwards. Last year, we were pleased to see Essilor unveil the first-year results of their Stellest™ lens, and it's wonderful to have them join us again in advancing education on this critical topic and sharing their knowledge and insights of clinical interventions to manage myopia. I look forward to an engaging session and presentation of the two-year results this year."*

Essilor previously [unveiled](#) the one-year interim findings of its Stellest™ lens at the World Society of Paediatric Ophthalmology and Strabismus (WSPOS) Worldwide Connect 2020 virtual congress for the first time. Stellest™ lens is Essilor's best solution to slow down myopia progression in children, with the H.A.L.T.² technology: a constellation of invisible³ lenslets. The

¹ Compared to single vision lenses, when worn 12 hours a day. Two-year prospective, controlled, randomized, double-masked clinical trial results on 54 myopic children wearing Stellest™ lenses compared to 50 myopic children wearing single vision lenses. Efficacy results based on 32 children who declared wearing Stellest™ lenses at least 12 hours per day every day. Bao J. et al. (2021). Myopia control with spectacle lenses with aspherical lenslets: a 2-year randomized clinical trial. Invest. Ophthalmol. Vis. Sci.; 62(8):2888.

² Highly Aspherical Lenslet Target

³ Aesthetic finish

two-year clinical research findings were also presented at the Annual Meeting of the ARVO (Annual Meeting of the Association for Research in Vision and Ophthalmology) on May 6, 2021.

Essilor International is the world's leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux®, Crizal®, Transitions®, Eyezen™, Xperio®, Foster Grant®, and Bolon™. It also develops and markets equipment, instruments and services for eyecare professionals. Essilor International is a subsidiary of EssilorLuxottica. For more information, please visit www.essilor.com

CONTACTS

Corporate Communications

Ginette De Matteis

Tel.: +33 (0)1 49 77 45 02

Media Relations

Mailis Thiercelin

Tel.: +33 (0)1 49 77 45 02